{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:27:03Z","timestamp":1777130823410,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intravenous artesunate (AS) is the first-line treatment for patients with severe imported malaria (SIM) worldwide. However, after 10 years of use in France, AS hasn\u2019t yet received marketing authorization.The purpose of this study was to assess the real-life effectiveness and safety of AS in the treatment of SIM in two Hospitals in France.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a bicenter retrospective and observational study. All patients treated with AS for SIM between 2014 and 2018 and 2016\u20132020 were included. The effectiveness of AS was evaluated by parasite clearance, number of deaths, and the length of hospital stay. The real-life safety was assessed by related adverse events (AE) and monitoring of biological blood parameters during the hospital stay and follow-up period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>110 patients were included during the six-year study period. 71.8% of patients were parasite-negative of their day 3 thick and thin blood smears after AS treatment. No patients discontinued AS due to an AE and no serious AE were declared. Two cases of delayed post-artesunate hemolysis occurred and required blood transfusions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study highlights effectiveness and safety of AS in non-endemic areas. Administrative procedures must be accelerated in order to obtain full registration and facilitate access to AS in France.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08260-6","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T15:02:27Z","timestamp":1685026947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of artesunate in the treatment of severe imported malaria in France: review of the effectiveness and real-life safety in two French university hospitals"],"prefix":"10.1186","volume":"23","author":[{"given":"M.","family":"Bonsergent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tching-Sin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bertault-Peres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lepelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Flet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"8260_CR1","unstructured":"World Health Organization. World malaria report 2022 [Internet]. WHO. World Health Organization; [cited 2023 Mar 23]. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2022."},{"key":"8260_CR2","unstructured":"Centre National de r\u00e9f\u00e9rence du Paludisme. Rapport annuel d\u2019activit\u00e9 2020. [Internet]. CNR Paludisme [cited 2023 Mar 23]. Available from: https:\/\/cnr-paludisme.fr\/wp-content\/uploads\/2021\/02\/Re%CC%81sume%CC%81-CNR-paludisme-2019.pdf."},{"key":"8260_CR3","unstructured":"World Health Organization. Guidelines for the treatment of malaria. Third edition [Internet]. WHO. World Health Organization; [cited 2023 Mar 23]. Available from: https:\/\/www.afro.who.int\/publications\/guidelines-treatment-malaria-third-edition."},{"key":"8260_CR4","doi-asserted-by":"crossref","unstructured":"Dondorp A, Nosten F, Stepniewska K et al. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet Lond Engl 2005 Sep 27;366(9487):717\u201325.","DOI":"10.1016\/S0140-6736(05)67176-0"},{"key":"8260_CR5","unstructured":"Dondorp AM, Fanello CI, Hendriksen ICE et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet Lond Engl 2010 Nov 13;376(9753):1647\u201357."},{"key":"8260_CR6","doi-asserted-by":"crossref","unstructured":"Udomsangpetch R, Pipitaporn B, Krishna S, et al. Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis. 1996 Mar;173(3):691\u20138.","DOI":"10.1093\/infdis\/173.3.691"},{"key":"8260_CR7","doi-asserted-by":"crossref","unstructured":"Sinclair D, Donegan S, Isba R et al. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012 Jun 13;2012(6).","DOI":"10.1002\/14651858.CD005967.pub4"},{"key":"8260_CR8","doi-asserted-by":"crossref","unstructured":"M\u00f8rch K, Strand \u00d8, Dunlop O et al. Severe malaria and artesunate treatment, Norway. Emerg Infect Dis 2008 Nov;14(11):1816\u20138.","DOI":"10.3201\/eid1411.080636"},{"key":"8260_CR9","doi-asserted-by":"crossref","unstructured":"Zoller T, Junghanss T, Kapaun A, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis. 2011 May;17(5):771\u20137.","DOI":"10.3201\/eid1705.101229"},{"issue":"1","key":"8260_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12936-016-1673-z","volume":"31","author":"F Kurth","year":"2017","unstructured":"Kurth F, Develoux M, Mechain M, et al. Severe malaria in Europe: an 8-year multi-centre observational study. Malar J. 2017;31(1):57.","journal-title":"Malar J"},{"key":"8260_CR11","unstructured":"European Medicines Agency. EU\/3\/07\/430 [Internet]. European Medicines Agency. 2018 [cited 2023 Mar 23]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu307430."},{"key":"8260_CR12","unstructured":"ANSM.: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. MALACEF. [Internet]. ANSM [cited 2023 Mar 23]. Available from: https:\/\/ansm.sante.fr\/tableau-acces-derogatoire\/malacef#."},{"key":"8260_CR13","unstructured":"Centers for Disease Control and Prevention. FDA Approval of Artesunate for Injection for Treatment of Severe Malaria. [Internet]. CDC [cited 2023 Mar 23]. Available from: https:\/\/www.cdc.gov\/malaria\/new_info\/2020\/artesunate_approval.html."},{"key":"8260_CR14","unstructured":"ANSM, PROTOCOLE D\u2019UTILISATION THERAPEUTIQUE ET DE RECUEIL D\u2019INFORMATIONS. MALACEF\u00ae (art\u00e9sunate) 60\u00a0mg, poudre et solvant pour solution injectable [Internet]. ANSM [cited 2023 Mar 23]. https:\/\/ansm.sante.fr\/uploads\/2022\/04\/21\/20210104-atun-malacef-put-v5-05-11-2017.pdf."},{"key":"8260_CR15","doi-asserted-by":"crossref","unstructured":"Marks ME, Armstrong M, Suvari MM, et al. Severe imported falciparum malaria among adults requiring intensive care: a retrospective study at the hospital for tropical diseases, London. BMC Infect Dis. 2013 Mar;5:13:118.","DOI":"10.1186\/1471-2334-13-118"},{"key":"8260_CR16","doi-asserted-by":"crossref","unstructured":"Kurth F, Zoller T. Reply to Jaureguiberry. Clin Infect Dis Off Publ Infect Dis Soc Am 2016 Jan 15;62(2):271.","DOI":"10.1093\/cid\/civ827"},{"key":"8260_CR17","doi-asserted-by":"crossref","unstructured":"Checkley AM, Smith A, Smith V, et al. Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: an observational study. BMJ. 2012 Mar;27:344:e2116.","DOI":"10.1136\/bmj.e2116"},{"key":"8260_CR18","doi-asserted-by":"crossref","unstructured":"Santos LC, Abreu CF, Xerinda SM, et al. Severe imported malaria in an intensive care unit: a review of 59 cases. Malar J. 2012 Mar;29:11:96.","DOI":"10.1186\/1475-2875-11-96"},{"key":"8260_CR19","doi-asserted-by":"crossref","unstructured":"Seringe E, Thellier M, Fontanet A, et al. Severe imported Plasmodium falciparum malaria, France, 1996\u20132003. Emerg Infect Dis. 2011 May;17(5):807\u201313.","DOI":"10.3201\/eid1705.101527"},{"key":"8260_CR20","doi-asserted-by":"crossref","unstructured":"Roussel C, Caumes E, Thellier M et al. Artesunate to treat severe malaria in travellers: review of efficacy and safety and practical implications. J Travel Med. 2017 Mar 1;24(2).","DOI":"10.1093\/jtm\/taw093"},{"key":"8260_CR21","doi-asserted-by":"crossref","unstructured":"Jaur\u00e9guiberry S, Thellier M, Ndour PA, et al. Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011\u20132013. Emerg Infect Dis. 2015 May;21(5):804\u201312.","DOI":"10.3201\/eid2105.141171"},{"key":"8260_CR22","doi-asserted-by":"crossref","unstructured":"Kurth F, Develoux M, Mechain M et al. Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015 Nov 1;61(9):1441\u20134.","DOI":"10.1093\/cid\/civ575"},{"key":"8260_CR23","doi-asserted-by":"crossref","unstructured":"Eder M, Farne H, Cargill T, et al. Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre. Pathog Glob Health. 2012 Jul;106(3):181\u20137.","DOI":"10.1179\/2047773212Y.0000000032"},{"issue":"2","key":"8260_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/cid\/ciz206","volume":"02","author":"N El Ket","year":"2020","unstructured":"El Ket N, Kendjo E, Thellier M, et al. Propensity score analysis of Artesunate Versus quinine for severe Imported Plasmodium falciparum Malaria in France. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;02(2):280\u20137.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"8260_CR25","unstructured":"ANSM.: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. MALACEF (art\u00e9sunate) 60\u00a0mg, poudre et solvant pour solution injectable - ATU nominative. [Internet]. ANSM [cited 2023 MAR 23]. Available from: https:\/\/ansm.sante.fr\/uploads\/2021\/04\/01\/20210401-atun-malacef-rapport-de-synthese-5.pdf."},{"key":"8260_CR26","doi-asserted-by":"crossref","unstructured":"Rolling T, Wichmann D, Schmiedel S, et al. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar J. 2013 Jul;15:12:241.","DOI":"10.1186\/1475-2875-12-241"},{"key":"8260_CR27","doi-asserted-by":"crossref","unstructured":"Arguin PM. Case definition: postartemisinin delayed hemolysis. Blood 2014 Jul 10;124(2):157\u20138.","DOI":"10.1182\/blood-2014-06-578922"},{"key":"8260_CR28","doi-asserted-by":"crossref","unstructured":"Itoda I, Yasunami T, Kikuchi K, et al. [Severe falciparum malaria with prolonged hemolytic anemia after successful treatment with intravenous artesunate]. Kansenshogaku Zasshi. 2002 Aug;76(8):600\u20133.","DOI":"10.11150\/kansenshogakuzasshi1970.76.600"},{"key":"8260_CR29","doi-asserted-by":"crossref","unstructured":"Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J. 2012 Mar;31:11:102.","DOI":"10.1186\/1475-2875-11-102"},{"key":"8260_CR30","doi-asserted-by":"crossref","unstructured":"Rolling T, Agbenyega T, Krishna S, et al. Delayed haemolysis after artesunate treatment of severe malaria - review of the literature and perspective. Travel Med Infect Dis. 2015 Apr;13(2):143\u20139.","DOI":"10.1016\/j.tmaid.2015.03.003"},{"key":"8260_CR31","doi-asserted-by":"crossref","unstructured":"Rehman K, L\u00f6tsch F, Kremsner PG, et al. Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2014 Dec;29:268\u201373.","DOI":"10.1016\/j.ijid.2014.09.007"},{"key":"8260_CR32","unstructured":"Organisation Mondiale de la Sant\u00e9. Note d\u2019information de l\u2019OMS sur l\u2019an\u00e9mie h\u00e9molytique tardive apr\u00e8s le traitement \u00e0 l\u2019art\u00e9sunate. [Internet]. WHO. World Health Organization; [cited 2023 Mar 23]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/338346."},{"key":"8260_CR33","doi-asserted-by":"crossref","unstructured":"Seguro AC, Campos SB. Diuretic effect of sodium artesunate in patients with malaria. Am J Trop Med Hyg. 2002 Nov;67(5):473\u20134.","DOI":"10.4269\/ajtmh.2002.67.473"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08260-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T15:02:49Z","timestamp":1685026969000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8260"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08260-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to the law of March 5, 2012 on experiments on human beings (n\u00b02012\u2009\u2212\u2009300, French legislation), our retrospective study is exempted from obtaining ethical approval from an ethics committee. This project does not fall into the category of research covered by the Jard\u00e9 Law because it is considered research not involving the human person within the meaning of Decree No. 2017\u2009\u2212\u2009884 of May 9, 2017 and therefore does not require consent to participate. This observational study is based solely on the examination of medical files and does not include either new questions asked (e.g. new quality of life questionnaires) and carried out in accordance with the declaration of Helsinki and the french legislation through the law of March 5, 2012 on experiments on human beings (n\u00b02012\u2009\u2212\u2009300, French legislation).Finally, each patient is informed, via the welcome booklet which is systematically handed out at the time of his or her care, of the following elements: \u201cunless you expressly object during your stay or at a later date, your clinical data collected as part of your care may be used at a later date by the establishment\u2019s personnel, or transmitted to scientific organizations in France or abroad, for the purposes of research in the health field\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"359"}}